1441PPhase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026. (23rd October 2018)

Record Type:: Journal Article
Title:: 1441PPhase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026. (23rd October 2018)
Main Title:: 1441PPhase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026
Authors:: Kawashima1, Y
Fukuhara, T
Furuya, N
Saito, H
Watanabe, K
Iwasawa, S
Tsunezuka, Y
Yamaguchi, O
Okada, M
Yoshimori, K
Nakachi, I
Gemma, A
Azuma, K
Hagiwara, K
Nukiwa, T
Morita, S
Kobayashi, K
Maemondo, M
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 8
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 8
Issue Display:: Volume 29, Issue 8 (2018)
Year:: 2018
Volume:: 29
Issue:: 8
Issue Sort Value:: 2018-0029-0008-0000
Page Start:
Page End:
Publication Date:: 2018-10-23
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy292.063 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12252.xml